Humira 40 mg solution for injection in pre-filled syringe clinical trials
4 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic confirmatory (Phase III)
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA)
This study looks at different medicines for children and young people with JIA whose current treatment hasn't worked well enough. We want to find out which medicine best helps control their arthritis and reduces symptoms like pain and tiredness after 6 months.
For: Juvenile Idiopathic ArthritisItaly · Netherlands · Germany - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Investigating the safety, feasibility, and optimal dose of fluorescently labeled Adalimumab-680LT for visualizing drug targeting in Inflammatory Bowel Diseases.
This study is looking at a new way to see how a medicine called adalimumab works in people with Inflammatory Bowel Disease (IBD). We're using a special version of the medicine that glows, so doctors can track it and understand its effects better.
For: Inflammatory Bowel Disease (IBD)Netherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects with Ulcerative Colitis Who Completed the Study M11-290
This study looks at the long-term safety of a treatment called Humira for children and teens with ulcerative colitis. It's for those who have already been on Humira in a previous study. We want to see how well they continue to do.
For: Ulcerative ColitisSlovakia · Poland - AuthorisedTherapeutic use (Phase IV)
Evaluation of a therapeutic de-eScalation strategy based on therapeutic drug MOnitOring in chronic non-infectious uveitis Treated witH adalimumab
This study looks at how well a medicine called Humira works for chronic eye inflammation (uveitis). It checks if reducing the dose, based on drug levels in the blood, keeps the inflammation under control and prevents infections over 48 weeks.
For: noninfectious uveitisFrance